KROS Keros Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1664710 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-83.4%
TTM net income YoY-195.8%
TTM EPS YoY-248.7%
Revenue 3-yr CAGR1,616.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-181.3%
Net margin-152.7%
FCF margin-119.4%
EBITDA margin-177.3%
Returns
ROE-12.6%
ROA-11.8%
ROIC (approx.)-389.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.00x
Current ratio18.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $243.86M | $0 | $151,000 | $0 | $20.10M |
| R&D expense | $129.64M | $173.63M | $135.26M | $87.27M | $55.14M |
| SG&A expense | $46.85M | $40.75M | $34.83M | $27.52M | $21.33M |
| Operating income | $67.57M | -$210.83M | -$169.94M | -$114.79M | -$56.37M |
| Interest expense | — | $0 | $0 | $1,000 | $4,000 |
| Pretax income | $91.90M | -$187.05M | -$152.99M | -$104.68M | -$56.73M |
| Income tax | $4.88M | $300,000 | $0 | $0 | $2.01M |
| Net income | $87.01M | -$187.35M | -$152.99M | -$104.68M | -$58.74M |
| EBITDA | $69.08M | -$209.60M | -$169.13M | -$114.12M | -$55.99M |
| EPS (basic) | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 |
| EPS (diluted) | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 |
| Weighted avg. shares (diluted) | 37.86M | 37.44M | 29.45M | 25.24M | 23.33M |
| Balance sheet | |||||
| Cash & equivalents | $287.42M | $561.38M | $332.36M | $279.05M | $231.37M |
| Receivables | $3.57M | $2.74M | $143,000 | $0 | $18.00M |
| Current assets | $315.43M | $588.89M | $347.29M | $285.77M | $251.44M |
| PP&E, net | $4.30M | $4.24M | $4.13M | $2.02M | $1.33M |
| Total assets | $338.02M | $615.89M | $370.02M | $306.78M | $255.25M |
| Current liabilities | $20.41M | $27.45M | $24.37M | $16.55M | $11.85M |
| Total liabilities | $34.89M | $44.33M | $37.81M | $29.36M | $12.08M |
| Shareholders' equity | $303.13M | $571.55M | $332.21M | $277.42M | $243.17M |
| Shares outstanding | 19.54M | 40.55M | 31.84M | 27.54M | 23.97M |
| Cash flow statement | |||||
| Operating cash flow | $107.50M | -$160.87M | -$124.51M | -$70.06M | -$62.15M |
| Capital expenditure | $1.55M | $1.93M | $2.46M | $1.24M | $1.02M |
| Free cash flow | $105.95M | -$162.80M | -$126.97M | -$71.30M | -$63.17M |
| Investing cash flow | -$1.55M | -$1.93M | -$2.46M | -$1.24M | -$1.02M |
| Financing cash flow | -$378.47M | $391.82M | $178.96M | $120.31M | $28.55M |
| Depreciation & amortization | $1.51M | $1.23M | $815,000 | $674,000 | $378,000 |
| Stock-based compensation | $28.70M | $34.87M | $28.76M | $18.68M | $11.72M |
| Share buybacks | $375.00M | $0 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.